Abstract: Dosage forms and methods for providing sustained release of reboxetine are provided. The sustained release dosage forms provide therapeutically effective average steady-state plasma reboxetine concentrations when administered once per day. This once-a-day dosing regimen results in only one peak plasma reboxetine concentration occurrence in each 24 hour period. In addition, the peak plasma reboxetine concentration occurs at a later time following dose administration and exhibits a lesser magnitude than the peak plasma reboxetine concentration that occurs following administration of reboxetine in an immediate-release dosage form.

Abstract: Dosage forms and methods for providing sustained release of reboxetine are provided. The sustained release dosage forms provide therapeutically effective average steady-state plasma reboxetine concentrations when administered once per day. This once-a-day dosing regimen results in only one peak plasma reboxetine concentration occurrence in each 24 hour period. In addition, the peak plasma reboxetine concentration occurs at a later time following dose administration and exhibits a lesser magnitude than the peak plasma reboxetine concentration that occurs following administration of reboxetine in an immediate-release dosage form.

Abstract: A dosage form, a therapeutic composition, and the use thereof is disclosed for administering a therapeutic agent accompanied by a pharmaceutically acceptable means administered for an indicated therapy.

Abstract: 2,3,5,6-Tetrachloropyridine, and 2,3-dichloro-5-(trichloromethyl)pyridine are prepared by selectively chlorinating polychlorinated .beta.-picolines in the vapor phase between about 250.degree. and 450.degree. C. in the presence of specific Lewis acid halide catalysts on an inorganic support. The gamma position on the pyridine ring is usually not chlorinated in the starting material or reaction products. These compounds are useful intermediates to produce insecticides and herbicides.

Abstract: 4-chlorobenzotrichloride was prepared by the chlorination of p-xylene in the vapor phase at a temperature above about 200.degree. C. in the presence of an activated carbon catalyst and water. An approximately 75 percent calculated yield was obtained at 250.degree. C. using a wide-pore activated carbon catalyst.

Abstract: Vapor phase chlorination of 2,6-dichloropyridine produces 2,3,6-trichloropyridine selectively over isomeric 2,4,6-trichloropyridine and of 2,3,6-trichloropyridine produces 2,3,5,6-tetrachloropyrindine in high selectivity over isomeric 2,3,4,6-tetrachloropyridine at temperatures of 300.degree. C. to 450.degree. C. The products are intermediates for insecticides and herbicides.

Abstract: Fluoropyridine compounds, including 3- and 5-fluoropyridines, are prepared in an improved process by contacting chloropyridine compounds with hydrogen fluoride in the vapor phase in the presence of an activated carbon catalyst having large diameter pores. Thus, 2,3-difluoro-5-(trifluoromethyl)pyridine is prepared by contacting 3-chloro-2-fluoro-5-(trifluoro-methyl)pyridine with excess hydrogen fluoride at about 500.degree. C. in the presence of an activated carbon catalyst having an average pore diameter of about 100 Angstroms.

Abstract: Novel 2,3-bis((poly)chloromethyl)pyridines and 3,6-dichloro--2-(polychloromethyl)pyridines were obtained by vapor phase chlorination of 2,3-lutidine. Chlorination at about 350.degree. C. using a 14.4 sec. residence time and a chlorine to 2,3-lutidine mole ratio of about 6.8, for example, produced 2-(chloromethyl)-3-(dichloromethyl) pyridine, 3-(chloromethyl)-2-(dichloromethyl)pyridine, 2,3-bis(dichloromethyl)pyridine, 6-chloro-2,3-bis(dichloromethyl)pyridine, 3-(dichloromethyl)-2-(trichloromethyl)pyridine, 6-chloro-3-(dichloromethyl-2-(trichloromethyl)pyridine, 6-chloro-2-(dichloromethyl)-3-(trichloromethyl)pyridine, and 3,6-dichloro-2-(trichloromethyl)pyridine. The compounds are useful as starting materials for herbicides and pharmaceutical agents.